Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma

Abstract EN

Background.

Soft-tissue sarcomas (STS) are a heterogeneous group of diseases with lack of effective treatments in most cases.

Previous data suggest that continuous infusional ifosfamide regimens might improve cytotoxicity and tolerability compared to standard schedules.

Methods.

We retrospectively report the outcome of 35 patients affected by STS treated with a 14-day infusional ifosfamide regimen (1000 mg/m2/day) in our institution.

Predictive factors for toxicity were also explored.

Results.

Median age was 53 years.

There were 16 males and 19 females.

Classification by histology was dedifferentiated liposarcoma (DDLPS): 22 (62.8%), synovial sarcoma: 7 (20%), myxoid/round-cell liposarcoma: 3 (8.5%), and others: 3 (8.5%).

Overall, 7 patients (20%) achieved partial response (PR) and 10 patients (29%) achieved stable disease (SD).

DDLPS showed special sensitivity: 5 patients (22.7%) had PR, 7 patients (31.8%) had SD, and disease control rate was 54.5%.

Median progression-free survival and overall survival were 4.2 and 11.2 months, respectively.

The most common toxicities were fatigue, nausea, and vomiting (all grades: 85.7%, 83%, and 54.3%, resp.).

Neither hypoalbuminaemia nor gender was found to predict toxicity, although encephalopathy predominantly affected females.

Conclusion.

Ifosfamide administered as a 14-day continuous infusion is a safe regimen in STS with notable activity in DDLPS.